Personnel Information

写真a

ANDO Fumiaki


Job title

Assistant Professor
To the head of this page.▲

Campus Career 【 display / non-display 】

  • 2017.04
    -
    2019.03
    Tokyo Medical and Dental University， (Old Organization)Medical Hospital， Hospital Departments， Department of Internal Medicine， Nephrology， Project Assistant Professor
  • 2019.04
    -
    2021.03
    Tokyo Medical and Dental University， Graduate School of Medical and Dental Sciences， Endowed Departments， Department of Nephrology and Regional Health(ibaraki)， Assistant Professor
  • 2020.04
    -
    Now
    Tokyo Medical and Dental University， Graduate School of Medical and Dental Sciences， Medical and Dental Sciences， Systemic Organ Regulation， Nephrology， Assistant Professor
  • 2021.04
    -
    2021.09
    Tokyo Medical and Dental University， (Old Organization)Medical Hospital， Hospital Departments， Department of Internal Medicine， Nephrology， Assistant Professor
  • 2021.10
    -
    2023.03
    Tokyo Medical and Dental University， Tokyo Medical and Dental University， Division of Clinical Medicine， Department of Internal Medicine， Nephrology， Assistant Professor
  • 2023.04
    -
    Now
    Tokyo Medical and Dental University， Graduate School of Medical and Dental Sciences， Medical and Dental Sciences， Systemic Organ Regulation， Nephrology， Assistant Professor

▼display all

To the head of this page.▲

Research Areas 【 display / non-display 】

  • Nephrology

To the head of this page.▲
 

Published Papers & Misc 【 display / non-display 】

  1. Yanagawa H, Hara Y, Ando F, Suzuki S, Fujiki T, Oikawa D, Yui N, Mandai S, Mori Y, Susa K, Mori T, Sohara E, Tokunaga F, Uchida S. LRBA signalosomes activate vasopressin-induced AQP2 trafficking at recycling endosomes. The Journal of physiology. 2023.12; 601 (23): 5437-5451. ( PubMed, DOI )

  2. Ando F, Hara Y, Uchida S. Identification of protein kinase A signalling molecules in renal collecting ducts. The Journal of physiology. 2023.04; ( PubMed, DOI )

  3. Suzuki S, Ando F, Kitagawa S, Hara Y, Fujiki T, Mandai S, Susa K, Mori T, Sohara E, Rai T, Uchida S. ZNF185 prevents stress fiber formation through the inhibition of RhoA in endothelial cells. Communications biology. 2023.01; 6 (1): 29. ( PubMed, DOI )

  4. Kurimoto Junki, Takagi Hiroshi, Miyata Takashi, Kawaguchi Yohei, Hodai Yuichi, Tsumura Tetsuro, Hagiwara Daisuke, Kobayashi Tomoko, Yasuda Yoshinori, Sugiyama Mariko, Onoue Takeshi, Iwama Shintaro, Suga Hidetaka, Banno Ryoichi, Katsuki Takeshi, Ando Fumiaki, Uchida Shinichi, Arima Hiroshi. Mineralocorticoids induce polyuria by reducing apical aquaporin-2 expression of the kidney in partial vasopressin deficiency ENDOCRINE JOURNAL. 2023; 70 (3): 295-304.

  5. Hara Y, Ando F*, Oikawa D, Ichimura K, Yanagawa H, Sakamaki Y, Nanamatsu A, Fujiki T, Mori S, Suzuki S, Yui N, Mandai S, Susa K, Mori T, Sohara E, Rai T, Takahashi M, Sasaki S, Kagechika H, Tokunaga F, Uchida S. LRBA is essential for urinary concentration and body water homeostasis. Proceedings of the National Academy of Sciences of the United States of America. 2022.07; 119 (30): e2202125119. ( PubMed, DOI )

  6. Ando F. Activation of AQP2 water channels by protein kinase A: therapeutic strategies for congenital nephrogenic diabetes insipidus. Clinical and experimental nephrology. 2021.10; 25 (10): 1051-1056. ( PubMed, DOI )

  7. Nanamatsu A, Mori T, Ando F, Furusho T, Mandai S, Susa K, Sohara E, Rai T, Uchida S. Vasopressin Induces Urinary Uromodulin Secretion By Activating PKA (Protein Kinase A). Hypertension (Dallas, Tex. : 1979). 2021.06; 77 (6): 1953-1963. ( PubMed, DOI )

  8. Fujiki T, Ando F*, Murakami K, Isobe K, Mori T, Susa K, Nomura N, Sohara E, Rai T, Uchida S. Tolvaptan activates the Nrf2/HO-1 antioxidant pathway through PERK phosphorylation Scientific Reports. 2019.06; 9 (1): 9245.

  9. Ando F, Uchida S. Activation of AQP2 water channels without vasopressin: therapeutic strategies for congenital nephrogenic diabetes insipidus. Clinical and experimental nephrology. 2018.06; 22 (3): 501-507. ( PubMed, DOI )

  10. Ando F, Mori S, Yui N, Morimoto T, Nomura N, Sohara E, Rai T, Sasaki S, Kondo Y, Kagechika H, Uchida S.. AKAPs-PKA disruptors increase AQP2 activity independently of vasopressin in a model of nephrogenic diabetes insipidus Nature Communications. 2018.04; 9 (1): 1411.

  11. Yui N, Ando F, Sasaki S, Uchida S. Ser-261 phospho-regulation is involved in pS256 and pS269-mediated aquaporin-2 apical translocation. Biochemical and biophysical research communications. 2017.08; 490 (3): 1039-1044. ( PubMed, DOI )

  12. Shoda W, Nomura N, Ando F, Mori Y, Mori T, Sohara E, Rai T, Uchida S. Calcineurin inhibitors block sodium-chloride cotransporter dephosphorylation in response to high potassium intake. Kidney international. 2017.02; 91 (2): 402-411. ( PubMed, DOI )

  13. Fumiaki Ando, Eisei Sohara, Tetsuji Morimoto, Naofumi Yui, Naohiro Nomura, Eriko Kikuchi, Daiei Takahashi, Takayasu Mori, Alain Vandewalle, Tatemitsu Rai, Sei Sasaki, Yoshiaki Kondo, Shinichi Uchida. Wnt5a induces renal AQP2 expression by activating calcineurin signalling pathway. Nat Commun. 2016.11; 7 13636. ( PubMed, DOI )

▼display all

To the head of this page.▲

Conference Activities & Talks 【 display / non-display 】

  1. Ando F. Identification of therapeutic targets for congenital nephrogenic diabetes insipidus. BENZON SYMPOSIUM No.66 2022.09

  2. Fumiaki Ando. Identification of an A-Kinase Anchor Protein Essential for Urinary Concentration. The 42nd Annual Meeting of the Korean Society of Nephrology. Basic Science Symposium. 2022.05.27

  3. Ando F, Uchida S. Development of Novel Therapeutic Strategies for Congenital NDI and Other PKA-Related Diseases. The 43th Annual Meeting of the Molecular Biology Society of Japan (MBSJ2020) 2020.12.03 web

  4. Ando F. 【大島賞受賞記念講演】Identification of Therapeutic Targets for Congenital Nephrogenic Diabetes Insipidus. 第63回日本腎臓学会学術総会 2020.08.18 横浜, web

  5. 安藤 史顕. AQP2制御の分子メカニズムの同定と先天性腎性尿崩症の治療薬開発(Identification of Molecular Mechanisms for AQP2 Regulation and Development of Therapeutic Drugs for Congenital Nephrogenic Diabetes Insipidus). 日本腎臓学会誌 2020.07.01

  6. Ando F, Yui N, Mandai S, Isobe K, Mori T, Susa K, Nomura N, Sohara E, Rai T, Uchida S. Derivatives of FMP-API-1/27 Robustly Activate AQP2 Water Channels Independently of Vasopressin. ASN Kidney Week 2019 2019.11

  7. Ando F, Yui N, Nomura N, Sohara E, Rai T, Sasaki S, Uchida S. AKAPs-PKA Disruptors Robustly Increase AQP2 Activity Independently of Vasopressin. The 52nd American Society of Nephrology, Kidney Week 2018 2018.10 San Diego

  8. Ando F, Sohara E, Yui N, Nomura N, Kikuchi E, Takahashi D, Mori T, Rai T, Sasaki S, and Uchida S.. Calcineurin is a target for the treatment of nephrogenic diabetes insipidus. . 3rd Next Generation Kidney Research Meeting. 2016.08 Tokyo

▼display all

To the head of this page.▲

Others 【 display / non-display 】

  • A Matter of Concentration: Molecular Mechanisms of Water Homeostasis，2022.08

To the head of this page.▲